services – 第 4 页

ACN Newswire

Sevens Atelier – Luxury Design and Build Consultancy, embarks on next phase of growth as a listed entity

July 6, 2022

Singapore, Jul 6, 2022 - (ACN Newswire via SEAPRWire.com) - Sevens Atelier Limited (the "Company" or "Sevens Atelier") would like to announce today its completion of the proposed acquisition of Sevens Creation Private Limited's Design and Build business. This will propel forward the Company's vision of a comprehensive and innovative Design and Build consultant for premium landed properties in Singapore. Headquartered in Singapore, Sevens Atelier taps on the expertise of a holistic in-house execution and advisory team, establishing itself as a premier Design & Build solutions provider with an innovative edge in the premium landed property space. The Company boasts a proven track record of notable design-build projects in prime residential districts, such as Orchard Rd, East Coast, Bukit Timah and Sentosa. Sevens Atelier is well-poised to build trust with its clients and continuously elevate their artisanal capabilities in the Design and Build space. As landed property prices in Singapore are expected to remain firm, if not experience an upward trend , demand for design consultancy services is also expected to face a corresponding increase, offering potential growth opportunities for the Company. Key services that will be offered and enhanced by the Company will include Redevelopment and Reconstruction as well as pre-purchase inspection of the homes. Going beyond consultation services for landed properties, as ancillary services to the Design and Build focus, Sevens Atelier will also provide access to pre-leasing consultation services for multinational companies and established players in the food and beverage industry, which will cover minute details such as lighting, furnishing, to turnkey visualisations, without the pressure of prematurely committing to the business space. Sevens Atelier is also set to launch 7s Meta Virtual Homes - to further integrate the physical and virtual aspects of home-building via an immersive 3D experience of virtual reality that will digitally enhance the Design and Build process. Commenting on the Company's listing status, Chief Executive Officer and Executive Director of Sevens Atelier, Mr. Jeffrey Hong said, "Luxury homes are both a financial and emotional investment, and we wish to operate as a comprehensive concierge service for our clients, leveraging on decades of real estate experience and network to build their dream homes. We are confident that Sevens Atelier will revitalise the home-building and luxury design consultancy space, as we continue to enhance our key offerings through investments in innovative digital solutions."About Sevens Atelier Limited (SGX:5EW)Sevens Atelier is a Catalist Board-listed company on the Singapore Exchange (SGX) offering full-fledged consultancy services in the Design & Build industry, including pre-leasing consultations of business spaces and pre-purchase inspections of premium landed properties in Singapore. From consultation to completion, they provide turnkey services to their premium clients. Sevens Atelier is a BCA-certified solutions provider in the Design and Build arena with the goal to constantly improve and evolve. Their artisanal capabilities are a hallmark of their commitment to their clients. For all media queries, please contact:Kamal SamuelFinancial PRT: 6438-2990E: kamal@financialpr.com.sg Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

SeaPRwire

ENNOVA Announces the Expansion of AUC Ecosystem through Mobile App ‘Tier’ and Crypto Exchange ‘LEO12’

July 5, 2022

Johannesburg, South Africa, NY, July 5, 2022 – (SEAPRWire) – ENNOVA, the fastest growing blockchain service company in South Africa, announces that they expand the ecosystem of the AUC project. African countries actively used mobile money as a measure to improve financial inclusion, and as mobile money lowered the threshold for financial use and increased access, financial inclusion in Africa doubled from 23% in 2011 to 43% in 2017. In particular, according to the results of the FinAccess 2021 survey conducted to measure the nation’s financial use and inclusiveness, Kenya’s use of financial services through official financial institutions such as banks grew rapidly from 26.7% in 2006 to 83.7%. Mobile money is nothing new. Even before the pandemic, African countries were trailblazers in the industry. Per McKinsey, “Just over half of the 282 mobile money services operating worldwide are located in Sub-Saharan Africa.” Today, it is not uncommon for more citizens to have access to mobile money than a traditional bank account. What is even more impressive is that there is still ample room for growth. Per the Wall Street Journal, only 45% of the African population has an active cell phone. To put this into perspective, in Europe, that figure hovers well above 80%. How these figures will be affected by the pandemic is anyone’s guess. In this situation, mobile money can effectively influence financial inclusion improvement beyond supply and demand limits. Mobile money has the advantage of being able to easily provide financial services to mobile phone users without installing a special financial infrastructure. In addition, as in the credit scoring system, credit is measured based on users’ mobile phone usage history, and services such as microloans can be provided to people with irregular income, low income, or low credit without a job. In particular, the ease of small transactions compared to banks can be effective in financial inclusion of the socially disadvantaged groups. Tier is a simple, easy, and fast payment and remittance app developed by Ennova that is a financial platform and service provider based in South Africa. The core platform of AUC project, which is conducted by Ennvoa, Tier, a mobile wallet, to register credit cards of various banks in the wallet to provide a service that allows you to conveniently purchase goods in general stores. In addition, pre-paid IC cards issued by Ennova can be registered, and if customers use them, they can purchase goods at a very low cost or receive various rewards through services provided by Ennova. Michael Kwon, co-Founder and managing director of Ennova, said, “We are a fintech and blockchain solution company that has been steadily conducting research and development for the past 3 years to provide more convenient online/offline payment services to African users.” he also added that “In the fast-growing simple payment market after the Covid-19 crisis, the Tier App will provide users with a more convenient digital payment environment and enable digital asset payment, providing high discount rates, low fees, and high security.” Furthermore, he said that “Currently, the entry of large companies such as PayPal into the digital asset payment market will attract more attention to the digital asset itself and increase demand, and if Tier App’s unique strengths are well utilized, it will definitely be able to erode demands from African markets.” Lastly, “We also introduce digital assets to Africa through the Leo12 exchange and provide a secure trading environment. It will provide support to blockchain startups in African continent through the LEO12’s Jump Deck program. With this ecosystem, we spread the advantages of digital finance to Africa and pursue sustainable development that grows together.” Currently, ‘Tier’ and ‘LEO12’ are already operating in South Africa and neighboring countries. Tier app and the LEO12 exchange are organically linked, and all users participating in the AUC ecosystem can use the AUC project’s digital assets, AUC tokens, and en-Cash points, to easily use cross-border payments and remittance services through the Tier app and the LEO12 exchange without using multiple solutions. Know more about LEO12 Crypto exchange, please visit www.leo12.com. About AUC Project The AUC is a project that starts with the financially underprivileged people in African continent and combines blockchain technology and digital asset into the global payment and remittance markets to provide relative solutions to users. AUC project’s ecosystem consists of digital financial platform, digital asset, and crypto exchange. AUC token issued on erc-20 based and used within the network of AUC projects such as transactions, remittances, and value exchanges between countries. As various applications are served on AUC tokens and as users increase, the demand for AUC tokens will increase and create higher value. Tier, digital financial platform, is a total payment and remittance platform made simple for everyone to enjoy all kinds of financial services in just one app. LEO12 is a digital asset exchange supporting 3 markets (ZAR/BTC/USDT) and 11 trading pairs and can buy/sell coins such as BTC, ETH, XRP, LTC and many more. LEO12 is now operating in South Africa and is scheduled to launch LEO12’s first branch in Ghana next year. For more information and updates about the project, please follow our website. We also periodically provide information on social media: Social Links Website: http://aucunited.com Telegram: https://t.me/aucproject Twitter: https://twitter.com/AUC_Project Medium: https://medium.com/@advancedunitedcont Facebook: https://www.facebook.com/AUC-advancedunitedcont-107106651420730 Media Contact Patrick Yu / Marketing Director support@ennovaglobal.com SOUCE: Ennova The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)

Perfect Medical Announces Final Results for FY2021/22

July 4, 2022

HONG KONG, Jul 4, 2022 - (ACN Newswire via SEAPRWire.com) - Perfect Medical Health Management Limited ("Perfect Medical" or the "Company", stock code: 1830.HK), one of the largest medical groups in Hong Kong, together with its subsidiaries (collectively referred to as the "Group"), is pleased to announce its annual results for the year ended 31 March 2022.Performance highlights-- The Company achieved a historical high revenue of HK$1.35 billion, representing a growth of 23.9%.-- Among the value of sales contract, aesthetic medical accounted for 66.0%, medical business accounted for 17.4% and beauty and wellness accounted for 16.6%.-- The Company achieved a satisfactory net profit of HK$305.2 million despite the impact of the pandemic. If excluding the government subsidies, the revised net profit after tax increased by 29.8%.-- The Company has expanded its geographical coverage to Hong Kong, China, Australia and Singapore, representing total service area increased by 39.0% to 322,000 sq.ft..-- Basic earnings per share increased by 2.1% to HK24.8 cents.-- To reward the shareholders' unwavering support, the Board recommended the payment of a final dividend of HK7.1 cents per share. Together with the interim dividend of HK17.7 cents per share, the total dividend per share is expected to be HK24.8 cents per share for the full year, representing a total dividend payout ratio of 100.0%.For the year under review, the Group's revenue increased by 23.9% to HK$1,350.0 million (FY2021: HK$1,089.8 million). The Group's EBITDA increased by 11.5% to HK$469.5 million (FY2021: HK$421.0 million). Profit attributable to shareholders of the Company was HK$305.2 million (FY2021: HK$284.6 million), representing a year-on-year increase of 7.2%, and a net profit margin of 22.6% (FY2021: 26.1%).During the year, the Group has geared up its service centre expansion pace in Hong Kong, China and overseas. Currently, the Group has expanded its penetration in strategic locations at office premises and shopping malls, with total GFA increasing by 39% to 322,000 square feet.Hong Kong OperationRevenue from Hong Kong Operation increased by 43.6% to HK$975.1 million (FY2021: HK$679.0 million), mainly attributable to revenue contribution in the aesthetic medical and medical businesses as well as the additional revenue contributed from the new service centres established in the past years, but offset by the closure of all service centres for 84 days since January 2022 owing to the Omicron outbreak. Currently, the Group has a well established network of service centres in Hong Kong covering a total of 198,000 square feet.The Company is mainly engaged in the operation of aesthetic medical and medical service in Hong Kong. From September to November 2021, the Company opened three service centres in Tsim Sha Tsui, Shatin and Central to consolidate its leading position in Hong Kong medical market.In terms of the medical service business, leveraging on the strong foundation in the aesthetic medical business in Hong Kong, the Group has consistently reviewed its service portfolio through providing additional value-added services to enhance the customers' stickiness. In addition, the Group has made subsequent investments in a range of medical services to boost cross-selling and lower the acquisition cost of the customers.Regions outside Hong KongRevenue from regions outside Hong Kong decreased by 8.8% to HK$374.8 million (FY2021: HK$410.8 million) due to the poor market sentiment and the continual lockdown under the pandemic. As of 31 March 2022, the Company has an extensive network in China, Macau, Sydney, Melbourne and Singapore, covering a gross service area of 124,000 square feet.As one of the pioneers in the aesthetic medical industry in China, the Group has been focusing on key coastal first tier cities in Southern and Eastern China as well as the country's capital in Beijing, in order to cultivate a premium branding image. With the escalating customers' demand on a more all-round and professional medical services, the Group hopes to foster a stronger operation loop and a synergy to better serve our customers.Prospects Dr. Au-Yeung Kong, the executive director, chairman and chief executive officer of Perfect Medical, said that "This year marks the 11th anniversary of the Company's listing on the Stock Exchange of Hong Kong Limited since 10 February 2012. Our business covers Hong Kong, China, Macau, Australia and Singapore. At present, the Company has built a one-stop service platform incorporating a comprehensive aesthetic medical and medical services, fully catered to customers' needs.With the weakening of the impact of the pandemic, the Company is well positioned to capitalize on the market opportunities and respond to the rebound of customers' demand in the post-pandemic era. In the future, the Company will gear up its effort organically, actively seek mergers and acquisitions of medical projects, and make optimisation and integration to offer additional high-quality services to our customers.Looking ahead, the Company will increase the proportion of medical services and proceed with the international business expansion, with a view to becoming a truly multinational medical group. For further information on the Group's FY2021/22 annual results, please refer to the Company's annual results announcement on the website of the Hong Kong Stock Exchange.https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0630/2022063000866.pdf About Perfect Medical Health Management LimitedPerfect Medical Health Management Limited is a multinational aesthetic medical corporate and one of the largest aesthetic medical companies in Hong Kong established in 2003. The Group focuses primarily on non-invasive aesthetic medical services and medical services in Hong Kong, China, Macau, Australia and Singapore with a total service area spanning approximately 322,000 square feet. Our operation offers a broad spectrum of professional services with assurance of utmost safety and efficacy. The Company was included as a constituent stock of the MSCI Hong Kong Small Cap Index on 27 May 2021, demonstrating the confidence from the capital market and recognising the investment value of the Company. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

EC Healthcare Announces FY2021/22 Annual Results

June 23, 2022

HONG KONG, Jun 23, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong, announces today its audited annual results for the fiscal year ended 31 March 2022 (the "Year").Business Highlight -- Sales volume achieved record high of HK$3,122.3 million, up 40.7% YoY-- Total revenue surged 40.3% YoY to a record high of HK$2,919.5 million-- Revenue from medical services segment increased significantly by 64.6% YoY to a record high of HK$1,689.0 million, boosting its revenue contribution to 57.9%-- Earnings before interest, taxes, depreciation, and amortization ("EBITDA") increased by 35.0% YoY to a record high of HK$536.4 million-- Net profit after tax for the Year was HK$270.5 million, increased by 19.9% YoY, basic earnings per share was 17.1 HK cents-- The board of directors (the "Board") proposed final cash dividend of 4.2 HK cents per share, which together with the interim dividend of 10.2 HK cents per share, will bring the total annual dividend to 14.4 HK cents per share, representing an annual dividend payout ratio of 84.2%-- As at 31 March 2022, the total valuation of the Group's M&A transactions completed was HK$641.1 million, spanning across veterinary, dental, and various medical specialties, which further strengthened the Group's medical services layout -- The Group's suite of medical services extends to 29 specialist disciplines, and the number of full-time and exclusive registered practitioners has increased to 251-- Total number of service points increased to 147, total gross floor area increased by 34.2% YoY to approximately 534,000 sq. ft-- The Group has been committed to its social responsibility during the COVID-19 pandemic by deploying resources to provide a wide range of anti-pandemic services, aiding the joint fight against the virus-- The Group maintained the leading role as the largest medical service provider (non-hospital) in Hong Kong in terms of revenue in 2021, according to Frost and SullivanDuring the Year, the Group's businesses demonstrated strong resilience to grow continually amidst a challenging operating environment caused by the fifth wave of the COVID-19 outbreak in Hong Kong, and further consolidated its leading position in the industry. The Group posted a record high sales volume of HK$3,122.3 million, up 40.7% year-on-year ("YoY"), while revenue also surged by 40.3% YoY to a record high of HK$2,919.5 million. Organic revenue increased by 49.8% YoY to HK$2,761.4 million, accounting for 94.6% of the total, thanks to the Group's long-term investments in technology, service, branding, corporate culture, and its flexible and effective operations management. During the Year, medical segment continued to be the key growth driver as medical revenue marked record high and increased significantly by 64.6% YoY to HK$1,689.0 million. The Group's EBITDA (earnings before interest, taxes, depreciation, and amortization) increased by 35.0% YoY to a record high HK$536.4 million. The Group's net profit after tax for the Year increased 19.9% YoY to HK$270.5 million, however net profit margin is under pressure of the suspension of the Group's beauty and wellness businesses in Hong Kong for a total of 104 days (total 84 days during the Year) in compliance with government pandemic control measures.The net profit attributable to equity shareholders of the Company increased by 2.4% YoY to HK$197.5 million. Basic earnings per share was 17.1 HK cents, compared to 18.8 HK cents for the same period last year. The board of directors proposed a final cash dividend of 4.2 HK cents per share. During the Year, the number of unique customers steadily increased to 182,300 (1) during the Year and the contribution from existing customers accounted for 64.3% (2 )to the Group's total revenue. Customer loyalty remained high with repurchase purchase rate of 90.2% (3). Driven by the synergies created by the Group's enclosed healthcare ecosystem, over 27.5% (4) of its customers have made purchases across its various brands in the Year. Meanwhile, the Group has maintained premium service quality with 99.96% (5) of customers' satisfaction rate. The Group maintained its leading role as the largest medical service provider (non-hospital) in Hong Kong in terms of revenue in 2021, according to Frost and Sullivan.Our number of service points increased through organic expansion and acquisition growth. During the Year, we have ventured into veterinary business and acquired 7 vet clinics and 2 vet advanced imaging centers. As at 31 March, 2022, the Group had total number of service points of 127 in Hong Kong, 4 in Macau and 16 in Mainland China with total gross floor area of approximately 534,000 sq. ft. Out of the net increase of approximately 136,000 sq. ft. floor area in FY2022, 71.9% came from the medical business and 28.1% from the aesthetic medical and beauty and wellness services business.Strong growth in medical segmentFor medical business, demand for the Group's medical services remained strong in FY2022. The Group continued to grow its market share through both organic and M&A growth strategies. Revenue from the Group's medical services segment increased significantly by 64.6% YoY to a record high HK$1,689.0 million, boosting its revenue contribution to 57.9%, of which organic expansion and M&A completed during FY22 accounted for 95.0% and 5.0% respectively. Organic growth is driven by surged demand for COVID-19 related services and rising healthcare sentiment. During FY22, the total valuation of acquisitions completed in medical segment was HK$460.7 million, spanning dental and various medical specialties. The Group's suite of medical services spans 29 specialist disciplines, and our headcount of full-time and exclusive registered practitioners has increased to 251.Resilient result from aesthetic medical and beauty and wellness services segmentFor aesthetic medical and beauty and wellness business, the Group demonstrated its resilience by achieving steady growth, thanks to the brand capital established over the years. During the Year, revenue contributed by aesthetic medical and beauty and wellness services increased by 10.2% YoY to HK$1,091.2 million. Revenue from Hong Kong remains stable at HK$804.7 million. Revenue from Mainland China increased by 28.4% YoY to HK$173.2 million, while revenue from Macau, China surged 119.6% YoY to HK$113.4 million due to a strong recovery of medical tourism.Embracing social responsibility by stepping up our response in the community during COVID-19As Hong Kong's leading private healthcare service provider, the Group stepped up during the COVID-19 pandemic to provide a wide range of anti-pandemic measures to the public. For example, we offered telemedicine and drug delivery services through our clinics as well as government-approved nucleic acid tests (RT-PCR) and antibody tests through our accredited laboratories. The Group also provides COVID-19 vaccinations to the public and has joined hands with charitable organizations to donate rapid test kits to those in need.Set up 2030 sustainability goals To assimilate sustainability into our business, the Group has taken a proactive approach to set up a sustainability working group with board of directors' oversight to execute our sustainability strategy. We have conducted stakeholder engagement surveys and set up our 2030 sustainability goals based on the findings. Operation & IT-related risks atop our stakeholders' concerns, we will further advance our operation protocols and have engaged third party consultant to review our data governance policy. Latest Business Developments after the Reporting PeriodAfter the annual reporting period, the Group has announced the acquisitions of two new medical businesses and formed one joint ventures, which will further expand the market share of the Group's medical business and extend the scope of the Group's medical services and its business presence.On 7 April 2022, the Group announced to acquire 75% of the issued share capital of a veterinary hospital in Tai Po for a total consideration of HK$15.75 million in cash. Upon completion, the Group will operate a total of 8 veterinary hospital, 2 veterinary imaging centers in Hong Kong.On 23 May 2022, the Group announced to acquire 75% of the issued share capital of Mobile Medical International Holdings Limited and its subsidiaries for a total consideration of HK$41.25 million in cash. Upon completion, the Group will operate a total of 6 health screening services centers, covering New Territories, Kowloon and Hong Kong Island, thereby further consolidating the health screening market in Hong Kong.On 6 June 2022, the Group announced to spearhead an unprecedented medical tenant - landlord collaboration and formed a joint venture with a real estate investment management company, KaiLong Group and Asia Allied Infrastructure Holdings Limited to co-build a premium purpose-built medical grade building in Hong Kong. The Group will be the anchor tenant of this Medical Building upon completion. The Group has conditionally agreed to make initial capital contributions to the joint venture company of up to HK$275 million, which will represent 30% of the total enlarged issued share capital of the joint venture company.On 21 June 2022, the Group signed its first sustainability-linked facility ("SLL Facility") totaling HK$ 700 million. This inaugural dual-tranche SLL Facility is a first-of-its-kind for a healthcare services provider in Hong Kong, complementing the Group's established status as a leading industry pioneer and reaffirms the importance of sustainability in the Group's future growth strategy. Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "The Group believes the medical market will remain relatively resilient under the challenging environment and public-private partnership will continue to increase Hong Kong's private medical spending in the long run. Looking forward, the Group we will diversify within medical and beauty sectors, which allow us to further increase in service offerings to our customers to better meet their needs. We will also continue to expand our strategic partnerships with key players in technology, telecom, property, insurance and pharmaceutical industries to form our healthcare ecosystem. The Group committed to uphold sustainability principles. Moving forward, we will excel through our sustainability journey together with our much-valued stakeholders. We will also be proactive in continuously refining our strategies for the overall welfare of our company and the greater community."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, a advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 20211. Based on revenue for the year2. Revenue contribution by existing customers to the total revenue for the year3. Customers of FY21 contribution in FY22 divided by the total revenue in FY214. Number of customers who purchased services from more than one brand for the year divided by total number of customers for the year 5. 100% minus the percentage of material unfavourable feedback of total revenue for the yearFor further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Charmaine Ip Tel: (852) 2136 6952 / 2169 0467 / 3920 7649 Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

EC Healthcare Signs Inaugural Dual-Tranche Sustainability-Linked Facility, The First-of-its-Kind in Hong Kong Healthcare Industry

June 21, 2022

HONG KONG, Jun 21, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce the signing of its first sustainability-linked facility ("SLL Facility") totalling HK$ 700 million with The Hongkong and Shanghai Banking Corporation Limited ("HSBC") as sole lender and sustainability structuring bank. The inaugural dual-tranche SLL Facility is a first-of-its-kind for a healthcare services provider in Hong Kong, complementing the Group's established status as a leading industry pioneer and reaffirms the importance of sustainability in the Group's future growth strategy. The SLL Facility is comprised of a revolving credit and a term loan, and the proceeds will be used for working capital.The Group is committed to the United Nations 2030 Sustainable Development Goals and has developed a number of clear targets against each of the environmental, social, and governance ("ESG") elements. These include reducing energy consumption, increasing employee engagement, and achieving a globally recognized standard in relation to corporate governance.SGS Hong Kong Limited, a leading sustainability consultancy firm, acted as ESG consultant on the SLL Facility.Ms. Ada Wong, Executive Director, Chief Strategy Officer & Chief Investment Officer of EC Healthcare said, "This maiden sustainability-linked facility is an important milestone and represents another bold step in the Group's sustainability journey. As the leading healthcare and medical services provider in Hong Kong, this transaction reflects the Group's desire to integrate sustainable development into its core business strategy as well as implement best practices into the daily operations of its various brands. We are delighted to align the Group's financing strategy with a number of impactful ESG goals, reinforcing our commitment to sustainability in the long-term. We are excited to set the stage for subsequent sustainable finance transactions in the Hong Kong healthcare market."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Charmaine Ip Tel: (852) 2136 6952 / 2169 0467 / 3920 7649 Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

JCN Newswire

Sony and Honda Sign Joint Venture Agreement to Establish New Company, “Sony Honda Mobility Inc.”, to Engage in Mobility Business

June 16, 2022

TOKYO, Jun 16, 2022 - (JCN Newswire via SEAPRWire.com) - Sony Group Corporation ("Sony") and Honda Motor Co., Ltd. ("Honda") announced today that they have signed a joint venture agreement to establish a new company to engage in the sale of high-value-added electric vehicles (EVs) and provide services for mobility. Today's announcement is the furtherance and result of discussion of a strategic alliance in the mobility field between the parties as announced in the joint press release entitled "Sony and Honda Sign Memorandum of Understanding for Strategic Alliance in Mobility Field" on March 4, 2022.The new company will aim to bring together Honda's cutting-edge environmental and safety technologies, mobility development capabilities, vehicle body manufacturing technology and after-sales service management experience, with Sony's expertise in the development and application of imaging, sensing, telecommunication, network and entertainment technologies, to realize a new generation of mobility and services for mobility that are closely aligned with users and the environment, and continue to evolve going forward.Sony and Honda plan to establish the new company within 2022 and to begin the sale of EVs and provision of services for mobility in 2025. The establishment of the new company and the start of business are subject to relevant regulatory approvals.New Company Overview (Planned)Company name: Sony Honda Mobility Inc.Location: Tokyo, JapanCapital: 10 billion yenInvestment ratio: Sony Group Corporation 50%, Honda Motor Co., Ltd. 50%Members of the board:Yasuhide Mizuno, Representative Director, Chairman and CEO Izumi Kawanishi, Representative Director, President and COO　Shugo Yamaguchi, Director and Deputy PresidentKojiro Okabe, Director and Executive Vice PresidentManabu Ozawa, Director (Honda Motor Co., Ltd.)Naoya Horii, Director (Sony Group Corporation)Comment from Kenichiro Yoshida, Representative Corporate Executive Officer, Chairman, President and CEO, Sony Group Corporation"Based on our vision to 'make the mobility space an emotional one,' Sony's initiatives in the mobility business are centered around the three areas of safety, entertainment and adaptability. As we continue our learnings in these areas, we are excited to have met a partner, Honda, with extensive global achievements and knowledge, and to sign the joint venture agreement between the two companies. Going forward, we aim to contribute to the evolution of mobility by combining Honda's cutting-edge environmental and safety technologies, mobility development capabilities, vehicle body manufacturing technology and after-sales service management experience, with our expertise in imaging, sensing, telecommunication, network and entertainment technologies."Comment from Toshihiro Mibe, Director, President, Representative Executive Officer and CEO, Honda Motor Co., Ltd."Honda continues to take on new challenges in the environmental, safety, and other advanced fields in order to be a driving force for social change through mobility, and 'become the power that supports people around the world who are trying to do things based on their own initiative'. We are very pleased to have signed a joint venture agreement with Sony, which has strengths in advanced digital technology, and shares our desire to take on new challenges. Since its announcement in March, many people have expressed their expectations for this joint venture. At the new company, we will strive to create new value through the fusion brought about by the combination of our different industries, so please look forward to future developments."Comment from Yasuhide Mizuno, Representative Director, Chairman and CEO of Sony Honda Mobility Inc. (Planned) and Senior Managing Officer of Honda Motor Co., Ltd."We are very pleased to sign this joint venture agreement, which represents the start line from which we embark on the major challenge of revolutionizing mobility and creating new value. We plan to fully leverage the technological assets the two companies possess in different fields, such as Sony's sensing technology and Honda's original mobility development capabilities, to realize mobility and services that inspire and excite our customers. By bringing together the expertise of both companies, we aim to lead the way in a new era."Comment from Izumi Kawanishi, Representative Director, President and COO of Sony Honda Mobility Inc. (Planned) and Executive Vice President of Sony Group Corporation"I am very pleased to have reached this day, which represents a major milestone in realizing the initiatives we have been working on until now with the aim of contributing to the evolution of mobility. By combining the many strengths of Sony and Honda, we intend to accelerate development and lead the evolution of mobility by realizing mobility as an emotional space rooted in safety and security, and the related services." Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

1 2 3 4